News

Medical Dialogues2d
GSK application for expanded use of RSV vaccine in adults aged 18-49 accepted in Japan
GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...
The Pharma Letter4d
GSK closer to Japanese Arexvy label expansion
Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...
Japan accepts GSK application for expanded use of RSV vaccine Arexvy
(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.
GSK hoping to expand Arexvy usage in Japan
Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...
Berkeley posts 5% drop in annual earnings, GSK's RSV vaccine gets expanded use in Japan
Housebuilder Berkeley posted a 5% fall in annual earnings but said it was confident about the future against a backdrop of falling interest rates and government plans to ramp up supply using ...
sharewise6d
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...
Zacks Investment Research on MSN6d
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human ...